148 related articles for article (PubMed ID: 35758043)
1. Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting.
Lombardi F; Belmonti S; Moschese D; Fabbiani M; Borghetti A; Ciccullo A; Visconti E; Di Giambenedetto S
HIV Res Clin Pract; 2022 Dec; 23(1):28-36. PubMed ID: 35758043
[No Abstract] [Full Text] [Related]
2. Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study.
Gagliardini R; Baccini M; Modica S; Montagnani F; Zanelli G; Borghetti A; Dreassi E; Lombardi F; Pecorari M; Borghi V; Callegaro A; Micheli V; Lodi MA; Rossetti B; Zazzi M;
J Glob Antimicrob Resist; 2022 Mar; 28():274-281. PubMed ID: 35092828
[TBL] [Abstract][Full Text] [Related]
3. Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study.
Lombardi F; Belmonti S; Borghetti A; Fabbiani M; Marchetti S; Tamburrini E; Cauda R; di Giambenedetto S
J Antimicrob Chemother; 2020 Jun; 75(6):1599-1603. PubMed ID: 32101614
[TBL] [Abstract][Full Text] [Related]
4. Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection.
Deng L; Li C; Chen P; Luo X; Zheng X; Zhou L; Zhou Y; Xia J; Hong Z
BMC Infect Dis; 2022 Jan; 22(1):17. PubMed ID: 34983415
[TBL] [Abstract][Full Text] [Related]
5. Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
Eron J; Hung CC; Baril JG; Slim J; Falcó V; Bogner J; Maggiolo F; Mills A; Sievers J; Man CY; Urbaityte R; Underwood M; Tenorio AR; Pappa KA; Wynne B; Koteff J; Gartland M; Smith KY; Aboud M
J Acquir Immune Defic Syndr; 2020 May; 84(1):60-65. PubMed ID: 31977595
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.
Rojas J; de Lazzari E; Negredo E; Domingo P; Tiraboschi J; Ribera E; Abdulghani N; Puig J; Mateo MG; Podzamczer D; Gutierrez MM; Paredes R; Clotet B; Gatell JM; Blanco JL; Martínez E;
Lancet HIV; 2021 Aug; 8(8):e463-e473. PubMed ID: 34358497
[TBL] [Abstract][Full Text] [Related]
7. Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine.
de Lazzari E; Negredo EB; Domingo P; Tiraboschi JM; Ribera E; Abdulghani N; Alba V; Fernández-Arroyo S; Viladés C; Peraire J; Gatell JM; Blanco JL; Vidal F; Rull A; Martinez E
J Antimicrob Chemother; 2024 May; 79(5):1133-1141. PubMed ID: 38546974
[TBL] [Abstract][Full Text] [Related]
8. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
[TBL] [Abstract][Full Text] [Related]
9. Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV.
Martínez-Sanz J; Ron R; Moreno E; Sánchez-Conde M; Muriel A; López Cortés LF; Blanco JR; Pineda JA; Mena Á; Calzado Isbert S; Moreno S; Serrano-Villar S
Front Immunol; 2022; 13():873408. PubMed ID: 35432298
[TBL] [Abstract][Full Text] [Related]
10. Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy.
Belmonti S; Lombardi F; Quiros-Roldan E; Latini A; Castagna A; Borghetti A; Baldin G; Ciccullo A; Cauda R; De Luca A; Di Giambenedetto S;
J Antimicrob Chemother; 2018 Jul; 73(7):1949-1954. PubMed ID: 29788156
[TBL] [Abstract][Full Text] [Related]
11. Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study.
Lombardi F; Sanfilippo A; Fabbiani M; Borghetti A; Ciccullo A; Tamburrini E; Di Giambenedetto S
J Antimicrob Chemother; 2023 Sep; 78(9):2315-2322. PubMed ID: 37534393
[TBL] [Abstract][Full Text] [Related]
12. Changes in Inflammatory Biomarkers When Switching from Three-Drug Regimens to Dolutegravir Plus Lamivudine in People Living with HIV.
Adachi E; Ikeuchi K; Koga M; Yotsuyanagi H
AIDS Res Hum Retroviruses; 2022 Dec; 38(12):881-883. PubMed ID: 36301933
[TBL] [Abstract][Full Text] [Related]
13. Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy.
Calza L; Colangeli V; Borderi M; Testi D; Granozzi B; Bon I; Re MC; Viale P
J Antimicrob Chemother; 2020 Nov; 75(11):3327-3333. PubMed ID: 32728708
[TBL] [Abstract][Full Text] [Related]
14. Dolutegravir Plus Lamivudine as Initial Therapy for HIV-1 Infected and ARV-naïve Patients in West China, 24-Weeks Results of a Preliminary Real-world Study.
Hui X; Gan X; Li Q; Sun W
Curr HIV Res; 2022; 20(3):222-227. PubMed ID: 35570525
[TBL] [Abstract][Full Text] [Related]
15. Real-World Experience with Two-Drug Regimens in HIV-1-Infected Patients Beyond the Indication of Clinical Trials: 48 Weeks' Results.
Arancón Pardo A; Moreno Palomino M; Jiménez-Nácher I; Moreno F; González Fernández MÁ; González-García J; Herrero Ambrosio A
AIDS Res Hum Retroviruses; 2021 Oct; 37(10):761-767. PubMed ID: 34465135
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients.
Maggiolo F; Gulminetti R; Pagnucco L; Digaetano M; Cervo A; Valenti D; Callegaro A; Mussini C
BMC Infect Dis; 2022 Oct; 22(1):782. PubMed ID: 36224538
[TBL] [Abstract][Full Text] [Related]
17. Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.
van Wyk J; Ait-Khaled M; Santos J; Scholten S; Wohlfeiler M; Ajana F; Jones B; Nascimento MC; Tenorio AR; Smith DE; Wright J; Wynne B
J Acquir Immune Defic Syndr; 2021 Jun; 87(2):794-800. PubMed ID: 33587500
[TBL] [Abstract][Full Text] [Related]
18. Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy.
Gillman J; Janulis P; Gulick R; Wallis CL; Berzins B; Bedimo R; Smith K; Aboud M; Taiwo B
J Antimicrob Chemother; 2019 Aug; 74(8):2365-2369. PubMed ID: 31039247
[TBL] [Abstract][Full Text] [Related]
19. Cytokines assets in PLWH in two-drug dolutergravir based or three-drug antiretroviral regimen.
Falasca K; Ucciferri C; Di Gasbarro A; Borrelli P; Di Nicola M; Frisenda C; Costantini E; Aielli L; Reale M; Vecchiet J
BMC Infect Dis; 2024 Jul; 24(1):665. PubMed ID: 38961336
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort.
Fabbiani M; Rossetti B; Ciccullo A; Oreni L; Lagi F; Celani L; Colafigli M; De Vito A; Mazzitelli M; Dusina A; Durante M; Montagnani F; Rusconi S; Capetti A; Sterrantino G; D'Ettorre G; Di Giambenedetto S;
HIV Med; 2021 Oct; 22(9):843-853. PubMed ID: 34318591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
